Both genetic and epigenetic alterations can control the progression of cancer, and epigenetic alterations are frequent in cancer. However, the functional effects of epigenetic alterations still remain unclear.
The approach of the project group is to use large scale 'omics data and advanced bioinformatic tools to identify cancer-promoting biological functions under epigenetic dysregulation, and to use CRISPR epigenetic editing to assess the causal regulatory role of epigenetic alterations. This knowledge will be used to develop refined classification of breast cancer patients and novel treatment strategies.
Project Group members
Thomas Fleischer (project leader)
- Lai X, Geier OM, Fleischer T, ..., A. Frigessi, Towards personalized computer simulation of breast cancer treatment: a multi-scale pharmacokinetic and pharmacodynamic model informed by multi-type patient data. Cancer Res 2019, PubMed 31118201
- Fleischer T*, Tekpli X*, ..., Kristensen VN, DNA methylation at enhancers identifies distinct breast cancer lineages, Nat Commun 2017, PubMed 29123100
- Fleischer T*, Klajic J*, ..., Kristensen VN, DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival, Oncotarget 2017, PubMed 27911866
- Fleischer T, ..., Kristensen VN (2014), Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis, Genome Biol 2014, PubMed 25146004